These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 19798025)

  • 21. Progressive multifocal leucoencephalopathy in the rheumatic diseases: assessing the risks of biological immunosuppressive therapies.
    Calabrese LH; Molloy ES
    Ann Rheum Dis; 2008 Dec; 67 Suppl 3():iii64-5. PubMed ID: 19022817
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The emergence of progressive multifocal leukoencephalopathy (PML) in rheumatic diseases.
    Boren EJ; Cheema GS; Naguwa SM; Ansari AA; Gershwin ME
    J Autoimmun; 2008; 30(1-2):90-8. PubMed ID: 18191544
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PML and rheumatology: the contribution of disease and drugs.
    Molloy ES
    Cleve Clin J Med; 2011 Nov; 78 Suppl 2():S28-32. PubMed ID: 22123931
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Drug-induced progressive multifocal leukoencephalopathy in multiple sclerosis: European regulators' perspective.
    Anton R; Haas M; Arlett P; Weise M; Balabanov P; Mazzaglia G; Prieto L; Keller-Stanislawski B; Raine J
    Clin Pharmacol Ther; 2017 Aug; 102(2):283-289. PubMed ID: 28001298
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Severe nontuberculous mycobacterial infection in 2 patients receiving rituximab for refractory myositis.
    Lutt JR; Pisculli ML; Weinblatt ME; Deodhar A; Winthrop KL
    J Rheumatol; 2008 Aug; 35(8):1683-5. PubMed ID: 18671331
    [No Abstract]   [Full Text] [Related]  

  • 26. Progressive multifocal leukoencephalopathy in rituximab-treated rheumatic diseases: a rare event.
    Berger JR; Malik V; Lacey S; Brunetta P; Lehane PB
    J Neurovirol; 2018 Jun; 24(3):323-331. PubMed ID: 29508305
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multiple sclerosis: Progressive multifocal leukoencephalopathy risk stratification.
    Pitarokoili K; Gold R
    Nat Rev Neurol; 2017 Dec; 13(12):710-712. PubMed ID: 29146954
    [No Abstract]   [Full Text] [Related]  

  • 28. Progressive multifocal leukoencephalopathy after rituximab in a patient with relapsed follicular lymphoma and low IgG levels and a low CD4+ lymphocyte count.
    Hopfinger G; Plessl A; Grisold W; Klimpfinger M; Höftberger R; Bernt R; Möstl M; Waldner R; Pittermann-Höcker E
    Leuk Lymphoma; 2008 Dec; 49(12):2367-9. PubMed ID: 19052987
    [No Abstract]   [Full Text] [Related]  

  • 29. Progressive multifocal leukoencephalopathy in multiple myeloma. A literature review and lessons to learn.
    Koutsavlis I
    Ann Hematol; 2021 Jan; 100(1):1-10. PubMed ID: 33009935
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Progressive multifocal leukoencephalopathy 11 years after liver transplantation: a case report.
    Moreno-Estébanez A; Almeida Velasco J; Pérez-Concha T; González-Pinto T; Gabilondo I
    J Neurovirol; 2017 Dec; 23(6):929-931. PubMed ID: 28900866
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Progressive multifocal leukoencephalopathy. Undesirable side effect of immunotherapy].
    Hartung HP; Warnke C; Hohlfeld R; Kieseier BC
    Nervenarzt; 2009 Oct; 80(10):1143-4, 1146-8, 1150-3. PubMed ID: 19357826
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Progressive multifocal leucoencephalopathy in a patient with systemic lupus erythematosus treated with rituximab.
    Harris HE
    Rheumatology (Oxford); 2008 Feb; 47(2):224-5. PubMed ID: 18045807
    [No Abstract]   [Full Text] [Related]  

  • 33. Rituxan warning.
    FDA Consum; 2007; 41(2):3. PubMed ID: 17582852
    [No Abstract]   [Full Text] [Related]  

  • 34. Progressive Multifocal Leukoencephalopathy Following Combined Rituximab-Based Immune-Chemotherapy for Post-transplant Lymphoproliferative Disorder in a Renal Transplant Recipient: A Case Report.
    Windpessl M; Burgstaller S; Kronbichler A; Pieringer H; Kalev O; Karrer A; Wallner M; Thaler J
    Transplant Proc; 2018 Apr; 50(3):881-883. PubMed ID: 29661457
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Progressive multifocal leukoencephalopathy after rituximab in a case of non-Hodgkin lymphoma.
    Kranick SM; Mowry EM; Rosenfeld MR
    Neurology; 2007 Aug; 69(7):704-6. PubMed ID: 17698796
    [No Abstract]   [Full Text] [Related]  

  • 36. Rituximab and progressive multi-focal leukoencephalopathy: the jury is deliberating.
    Carson KR; Bennett CL
    Leuk Lymphoma; 2009 Mar; 50(3):323-4. PubMed ID: 19347724
    [No Abstract]   [Full Text] [Related]  

  • 37. Immunogenicity of biologic agents: a new concern for the practicing rheumatologist?
    Haraoui B; Pelletier JP; Martel-Pelletier J
    Curr Rheumatol Rep; 2007 Aug; 9(4):265-7. PubMed ID: 17688834
    [No Abstract]   [Full Text] [Related]  

  • 38. No evidence for an early excess incidence of progressive multifocal leukencephalopathy in HIV-infected patients treated with rituximab.
    Hoffmann C; Gérard L; Wyen C; Oksenhendler E
    J Acquir Immune Defic Syndr; 2012 Aug; 60(5):e121-2. PubMed ID: 22820725
    [No Abstract]   [Full Text] [Related]  

  • 39. Infratentorial progressive multifocal leukoencephalopathy in a patient treated with fludarabine and rituximab.
    Bonavita S; Conforti R; Russo A; Sacco R; Tessitore A; Gallo A; Della Corte M; Monsurrò MR; Tedeschi G
    Neurol Sci; 2008 Feb; 29(1):37-9. PubMed ID: 18379739
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacovigilance and PML in the oncology setting.
    Bennett CL
    Cleve Clin J Med; 2011 Nov; 78 Suppl 2():S13-7. PubMed ID: 22123927
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.